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Introduction: Peutz–Jeghers syndrome is an autosomal dominant disease with incomplete penetrance and variable
expression caused by germline mutation of serine threonine kinase 11/liver kinase B1; it is characterized by
hamartomatous polyps in the gastrointestinal tract, mucocutaneous melanin pigmentation, and increased
predisposition to neoplasms. In Peutz–Jeghers syndrome, bilateral Sertoli cell testicular tumors cause endocrine
manifestations including gynecomastia and feminization.
This study aimed to assess the role of breast ultrasound in the evaluation of the effectiveness of an innovative
surgical approach.
Case presentation: This report presents a pair of European 9-year-old identical male twins with Peutz–Jeghers
syndrome, bilateral prepubertal gynecomastia, and testicular multifocal calcifications. Both twins were treated with
anastrozole for 2 years. After finishing treatment, both underwent subcutaneous mastectomy performed by the
“modified” Webster technique. Breast examination and ultrasound were performed before and after the pharmacological
and surgical treatment. A breast ultrasound scan before surgery showed bilateral gynecomastia in both patients. No solid
nodular or cystic formations were present on either side. After pharmacological therapy and surgical glandular removal,
a breast examination showed a significant reduction in breast volume; 1 year after surgery, a breast ultrasound scan of
both patients showed a total absence of glandular parenchyma, with muscle planes well represented.
Conclusions: Breast examination and ultrasound have proved to be a valid approach in the assessment of the
treatment of prepubertal gynecomastia because they allow the efficacy of the pharmacological and surgical
treatment to be evaluated in a multidisciplinary approach to one of the most frequent endocrine manifestations
of Peutz–Jeghers syndrome.
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Peutz–Jeghers syndrome (PJS) is an autosomal dominant
disease with incomplete penetrance and variable expres-
sion [1,2] caused by germline mutation of serine threonine
kinase 11 (STK11/liver kinase B1, LKB1) [3,4].
It is characterized by increased predisposition to neo-
plasms [5] and hamartomatous polyps in the gastrointes-
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unless otherwise stated.high phenotypic variability. In PJS, high aromatase activity
[6] causes oversecretion of estrogen by bilateral Sertoli cell
testicular tumors (large-cell calcifying tumors) with ad-
vanced bone age, feminization and gynecomastia.
Gynecomastia is a benign condition characterized by
enlargement of the male breast due to proliferation of
glandular tissue; it is common in normal males during
the neonatal period, at early puberty, and with increasing
age. Prepubertal gynecomastia is characterized by the pres-
ence of palpable uni- or bilateral breast tissue in boys with-
out other signs of sexual maturation. It could be related
with excessive estrogen production by adrenal or testicularal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tal adrenal hyperplasia, or overexpression of aromatase
or to the use of drugs that affect androgen and estrogen
production and metabolism. This case report describes
the role of breast ultrasound in the surgical management
of prepubertal gynecomastia and subsequent follow-up
in monozygotic twins with PJS and bilateral multifocal
testicular calcifications.
Case presentation
A pair of European 9-year-old identical male twins (patients
1 and 2) with PJS presented with bilateral progressive pre-
pubertal gynecomastia over the course of 1 year. The family
history showed that their father had PJS but no history of
gynecomastia or testicular calcification. Neither mutations
nor deletions where found in the tumor suppressor gene
LKB1/STK11, which is responsible for approximately 60%
of PJS cases.
The twins arrived at our Department in 2008. A phys-
ical examination showed two boys with pigmented lesions
of the lips and bilateral gynecomastia with a diameter of
9cm in patient 1 and 7cm in patient 2, corresponding to a
female Tanner stage B3. Their testicular volume was 4mL
bilaterally. The boys’ penises were infantile, and they had
no pubic or axillary hair (pubic hair, PH1; genitalia devel-
opment, G1).
The height of patient 1 was 129.2cm (25th percentile),
with a growth velocity of 7cm/year (90th percentile for age)
and normal weight for height. The height of patient 2 was
125.5cm (10 to 25th percentile), with a growth velocity
of 6cm/year (75 to 90th percentile) and normal weight
for height. The target height was 173cm (−0.7 Standard
Deviation Score, SDS).
Hormonal treatment
Hematic levels of sexual hormones were constantly veri-
fied with specific reference to luteinizing hormone (LH),
follicle-stimulating hormone (FSH), prolactin, testosterone,
estrone and estradiol.
Baseline endocrine investigations in patients 1 and 2
showed normal prepubertal serum concentrations ofTable 1 Breast ultrasound monitoring of gynecomastia and g




Breast growth (cm/year) Patient 1 7 3 5
Patient 2 6.6 3 3.5
Gynecomastia (cm) Patient 1 9 4 4
Patient 2 7 3 3testosterone, FSH, LH and dehydroepiandrosterone sul-
fate, as well as slightly elevated levels of estradiol, with
normal levels of estrone.
Both boys were treated with the third-generation aro-
matase inhibitor, anastrozole, starting dose of 1mg orally
once daily. The decision to treat the boys with the aro-
matase inhibitor anastrozole had been implemented to
reduce gynecomastia and to prevent the accelerating effect
of estrogen excess on skeletal maturation.
Samples were obtained before the beginning of the ana-
strozole treatment, then after 1 and 2 years of treatment,
during 2-years follow-up evaluation, before and after 3
months subcutaneous mastectomy surgery.
During the period of anastrozole treatment, a reduction
of gynecomastia was observed more in one twin than in
the other. In particular, during the first year of treatment,
growth velocity decreased from 7 to 3cm and gynecomastia
decreased from 9 to 4cm in diameter in patient 1, whereas
growth velocity decreased from 6.6 to 3cm/year and
gynecomastia decreased from 7 to 3cm in diameter in
patient 2.
During the second year of treatment, no changes in
gynecomastia occurred, and growth velocity reverted to
normal values for age in patient 1 (5cm/year), whereas
it remained below the normal value for age in patient 2
(3.5cm/year).
After 2 years, a sharp reduction in growth velocity oc-
curred for both patients (although it was more pronounced
in patient 2, with a growth velocity of 1.6cm/year, 3rd per-
centile), which prompted a reduction in the anastrozole
dose and then its withdrawal at the age of 11.5 years.
After a washout period of 6 months, clinical reevaluation
of both twins showed regrowth of gynecomastia, corre-
sponding to a female Tanner stage B3, with resumed ten-
derness of the breast to palpation (Table 1, Figure 1).
Bone age
To determine bone age, X-rays of each patient’s non-
dominant hand and wrist were analyzed by the TW2
method before anastrozole treatment was started, and
after 1 year of treatment and 2 years of treatment.rowth before treatment (enrollment), during 2 years of









year >2 years 2 years
6 months
5 6 0 0
1.6 3.6 0 0
4 5 0 0
3 6 0 0
Figure 1 a) breast volume, b) breast growth in patients 1 and 2 at enrollment, first year, second year, after 2 years of medical
treatment, at 2 years and 6 months (after medical treatment interruption, before surgical treatment), and 1 month and 1 year after
surgery. In the vertical line we consider years of patients, from 0 to 18 years old. pz, patient; M, months; Y, years.
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patient 2, with an advance of approximately 2.5 years
and an adult height prognosis of 157cm (−3 SDS) for
patient 1 and 158.7cm (−2.8 SDS) for patient 2 (both
below the target height).
Ultrasound findings
Ultrasound was performed using a Logiq S6 scanner (GE
Healthcare, Waukesha, WI, USA) with a multifrequency
matrix-array linear transducer (7 to 14MHz) and a multi-
frequency convex transducer (3.5 to 5Mhz).
A breast ultrasound to assess palpable masses was per-
formed during and after pharmacological treatment, be-
fore and after 1 month and 1 year from subcutaneous
mastectomy surgery. The examinations showed bilateral
gynecomastia with typical hyperechoic fibroglandular tis-
sue. No solid nodular or cystic formations were present
on either side.
An abdominal ultrasound scan of their adrenal glands
and a testicular ultrasound scan were performed to analyze
the presence of estrogen-producing adrenal tumor; aFigure 2 Patient 1. Clinical preoperative breast view (a) and breast ultraso
cystic formations are present on either side; clinical postoperative breast vi
total absence of glandular parenchyma, with muscle planes well representetesticular ultrasound scan showed bilateral multifocal
calcifications.
Surgical treatment
At the age of 13 years, the twins underwent gynecomastia
surgical treatment, using the Webster technique. A skin
incision was made below the areola edge and the adipose
and glandular tissues were significantly removed under
direct vision from the skin at the top and from the pec-
toral muscle at the bottom; the removed breast tissue was
sent to a pathologist.
The result was radical surgery (thus avoiding recur-
rence) and a good aesthetic result.
In both boys, an advancement flap of adipose tissue
below the nipple–areola complex was placed, in consider-
ation of the underlying disorder, to avoid leaving a residual
subareolar glandular parenchyma (Figures 2 and 3).
Although the glandular tissue had been completely re-
moved, this technique allowed a good aesthetic result, thus
avoiding depression of the nipple–areola complex, which
would remain responsive to the circulating estrogen.und (b,c) scan showing bilateral gynecomastia. No solid nodular or
ew (d) and breast ultrasound (e,f) scan 1 year after surgery showing a
d.
Figure 3 Patient 2. Clinical preoperative breast view (a) and breast ultrasound (b,c) scan showing bilateral gynecomastia. No solid nodular or
cystic formations are present on either side; clinical postoperative breast view (d) and breast ultrasound (e,f) scan 1 year after surgery showing a
total absence of glandular parenchyma, with muscle planes well represented.
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functional impairment of their arms or reduction in
nipple–areola complex sensitivity. Wound healing was
completed in 10 days, and scars were almost undetectable
in both cases. The excessive removal of parenchyma did
not result in skin irregularities, avoiding any unnecessary
subsequent treatment. Both patients received postopera-
tive pain management with painkillers according to their
weight. The clinical course had no irregularities. No surgi-
cal infections or hematomas were reported. Although
the breast gland had been totally removed, both patients
had good cutaneous retraction and no nipple or areola
necrosis or deformity, as confirmed by ultrasound picture
control.
Histologic findings confirmed their condition to be
benign. After surgical glandular removal, a breast exam-
ination showed a significant reduction in breast volume;
1 year after surgery, a breast ultrasound scan of both
patients showed a total absence of glandular parenchyma,
with muscle planes well represented.
A compressive medication was applied after surgery
with a chest bandage for 4 weeks.
Analgesics were prescribed only in case of pain. Both
boys were observed by surgeons 1 and 4 weeks after
surgery for removal of the bandage and to exclude the
onset of hematomas, seromas, skin infections, keloids
and pain.
Follow-up
After surgery, the twins were followed for an additional
year for evaluation of sex hormone levels, growth curve
and breast size.
Discussion
Gynecomastia is a multifactorial disease, primarily de-
pendent on the balance between free estradiol and free
testosterone. Estrogen biosynthesis results from theproduction of androgens from steroid precursors; there-
fore, an excess of endogenous estrogen can be a result of
an increase in substrate, aromatase activity, or both.
An increase in the level of estrogen is the most com-
mon cause of imbalance. The most common causes of
gynecomastia are endocrinopathies, neoplasm-producing
estrogens, human chorionic gonadotropin or aromatase,
hyperaromatase syndrome [6] and only few cases of
idiopathic prepubertal disease. The frequencies of some
remaining causes have been estimated as follows: cirrho-
sis (8%), primary hypogonadism (8%), testicular tumors
(3%), secondary hypogonadism (2%), hyperthyroidism
(1.5%), and renal disease (1%).
Testicular cancer (associated with both germ cell tumors
and non-germ cell tumors) accounts for 1 to 1.5% of all
male neoplasms. Although PJS represents one of the
genetic conditions predisposing to these types of tumors,
it remains a rare condition [10-13]. Our two patients with
PJS with large-cell calcifying Sertoli cell tumors had pre-
pubertal gynecomastia for approximately 1 year (Tanner
stage 3) and had advanced bone age from the increased
level of serum estradiol.
The treatment of prepubertal gynecomastia depends on
its etiology. Medical therapy with an aromatase inhibitor
alone is not effective in reversing prepubertal gyne-
comastia. The initial florid stage, characterized by ductal
proliferation, can respond to medical treatment but, sub-
sequently, glandular hyperplasia is replaced by progressive
fibrosis and hyalinization; when it causes painful or psy-
chological disturbance, surgical removal of the breast
glandular tissue is indicated [10,14].
However, anastrozole represents the first noninvasive
step of treatment in PJS and may be useful for delaying
surgery in very young patients to achieve an optimal
aesthetic result. Plastic surgeons used a standard mast-
ectomy through a semicircular incision within the margin
of the pigmented area of the areola to conceal the scar.
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mm pad under the nipple to prevent dermal adherence to
the pectoralis fascia. To prevent possible recurrence, they
totally removed the gland and set up an advancement flap
of adipose tissue to prevent adhesion of the nipple to the
pectoralis fascia and its unaesthetic depression.
In conclusion, gynecomastia is a multifactorial disorder,
and a correct evaluation must be performed to distinguish
physiologic and pathologic causes. The history must in-
clude testicular assessment symptoms of hepatic disease
and alcohol consumption as well as family history. Phys-
ical examination and a routine biochemical profile permit
an acknowledgement and recognition of most underlying
causes.
Conclusions
Although severe gynecomastia is a rare condition in the
pediatric age, competence and expertise is necessary for
the treatment of these patients. Breast examination and
ultrasound have proved to be a valid approach in the as-
sessment of the treatment of prepubertal gynecomastia
because they allow the efficacy of the pharmacological
and surgical treatment to be evaluated in a multidiscip-
linary approach to one of the most frequent endocrine
manifestations of PJS.
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